FedEx Launches Dedicated Life Sciences Business to Strengthen Global Healthcare Logistics

FedEx_BLR_flight_launch

FedEx Corp has announced the launch of FedEx Life Sciences, a dedicated business focused on supporting the global transportation of pharmaceuticals, biologics, medical devices, clinical trial materials and other critical healthcare shipments. The new organization has been established to meet the growing demand for specialized logistics solutions as healthcare supply chains become more complex and time-sensitive.

The launch brings together FedEx’s global transportation network, specialized healthcare expertise and advanced shipment monitoring technologies to help pharmaceutical companies, healthcare providers and life sciences organizations move critical products with greater speed, visibility and reliability. The healthcare industry is witnessing rapid growth in advanced therapies, biologics and precision medicine, increasing the need for logistics solutions capable of maintaining strict quality standards while meeting regulatory requirements across international markets. FedEx Life Sciences has been created to provide end-to-end support for these specialized supply chains, including the transportation of temperature-sensitive medicines, clinical trial materials and patient-critical shipments.

To lead the new organization, FedEx has appointed Nick Gennari as President, Healthcare and Life Sciences. Gennari, who joined the company in 1992, has more than three decades of experience in developing logistics and supply chain solutions for global healthcare, aerospace and technology customers. Since taking charge of the healthcare business in 2024, he has played a key role in expanding FedEx’s healthcare operations, which now generate approximately US$10 billion in annual revenue worldwide.

Brie Carere, Executive Vice President and Chief Customer Officer at FedEx, said healthcare logistics requires a highly specialized network capable of supporting patient-critical deliveries with precision and reliability. She noted that every shipment has the potential to impact researchers, medical professionals and patients, making speed, visibility and operational excellence essential. She added that FedEx Life Sciences combines the company’s logistics infrastructure, advanced monitoring capabilities and industry expertise to build more resilient healthcare supply chains.

The new organization builds on recent investments made by FedEx to strengthen its healthcare logistics capabilities. In 2025, the company received the International Air Transport Association (IATA) CEIV Pharma Corporate Certification for its ground handling operations across its global air hubs and ramps. FedEx has also established a dedicated global quality leadership team to oversee quality management systems and support compliance with pharmaceutical and medical device industry standards.

The company has expanded its healthcare infrastructure with six Life Sciences Centers worldwide and recently introduced a direct air service connecting Indianapolis and Dublin, improving connectivity between two major pharmaceutical manufacturing hubs and supporting faster movement of healthcare products across the Atlantic.

FedEx Life Sciences also leverages FedEx Surround, the company’s intelligent shipment monitoring platform that uses machine learning to provide end-to-end visibility, identify potential disruptions and enable proactive intervention for critical shipments where timing, temperature control and reliability are essential.

Nick Gennari said healthcare supply chains continue to evolve as new therapies and medical technologies reach patients around the world. He added that the dedicated organization will provide customers with specialized expertise, stronger operational coordination and the confidence needed to transport life-saving healthcare products safely and efficiently.

FedEx operates one of the world’s largest transportation and logistics networks, serving customers in more than 220 countries and territories. With annual revenue of approximately US$86 billion and a workforce of more than 450,000 employees, the company continues to invest in advanced technologies and specialized logistics solutions to support the future of global healthcare delivery.